Professor Roger Reddel (BSc (Med) MBBS PhD FRACP FAAHMS FAA) has been Director of Children's Medical Research Institute (CMRI), and the Sir Lorimer Dods Professor, Sydney Medical School, University of Sydney, since 2007. He is also Head of CMRI's Cancer Research Unit, Director of CellBank Australia and Co-Director of ProCan®.
He obtained his medical degrees from the University of Sydney, trained in medical oncology at Royal Prince Alfred Hospital, and is a registered medical practitioner and Fellow of the Royal Australasian College of Physicians. Roger completed a PhD in cancer cell biology at the Ludwig Institute for Cancer Research in the University of Sydney's Department of Cancer Medicine, and received an NHMRC CJ Martin Fellowship and a Fulbright Fellowship to undertake postdoctoral research at the National Cancer Institute, Bethesda, Maryland, USA.
He returned to Sydney to establish the Cancer Research Unit at CMRI, with the support of Cancer Council NSW's Bicentennial Fellowship. He has continued to receive major support from Cancer Council NSW, including being awarded the Carcinogenesis Fellowship for ten years, and Program Grants for ten years. His team is also supported by Cancer Institute NSW, Australian Cancer Research Foundation, the Judith Hyam Memorial Trust Fund for Cancer Research, National Breast Cancer Foundation and the National Health and Medical Research Council of Australia.
Professor Reddel was elected as a Fellow of the Australian Academy of Science and of the Australian Academy of Health and Medical Sciences, and has been awarded the Ramaciotti Medal for Excellence in Biomedical Research, the NSW Premier's Award for Outstanding Cancer Researcher of the Year, and the Neil Hamilton Fairley Medal of the Royal Australasian College of Physicians.
Professor Reddel has been Director of the Institute since 2007 and serves on the Institute’s Finance and Investment Committee.
The Cancer Research Unit conducts trailblazing work on telomeres, which are important for senescence (aging) and all cancers. Our main emphasis is on understanding how cancer cells continue to proliferate using the Alternative Lengthening of Telomeres (ALT) mechanism. Better understanding of this mechanism will enable us to develop better treatments against ALT cancers, which are some of the most aggressive types, including glioblastoma brain tumours and osteosarcomas.